Hematocrit: How to Interpret Your Result

What Hematocrit Actually Measures

Hematocrit (Hct) represents the fraction of whole blood composed of red blood cells, expressed as a percentage. A CBC panel spins or calculates this value from hemoglobin concentration, mean corpuscular volume, and red cell count. The number tells your clinician how efficiently your blood can carry oxygen.

Red blood cells contain hemoglobin, the protein that binds oxygen in the lungs and releases it in peripheral tissues. When hematocrit rises, blood viscosity increases. When it drops, oxygen delivery to organs may fall. Both directions carry clinical consequences.

The measurement itself is straightforward. A standard venous blood draw fills an EDTA tube, and modern hematology analyzers report the result within hours 1. Unlike many biomarkers that require fasting, hematocrit does not. Hydration status, however, affects the reading. A patient who is dehydrated will show a falsely elevated hematocrit because plasma volume has contracted, concentrating the red cells that remain. This is why a single out-of-range value almost always warrants a repeat draw under controlled hydration conditions before any diagnosis is made 2.

Normal Hematocrit Ranges and What Shifts Them

For adult men, most U.S. laboratories report a reference range of 38.3% to 48.6%. For adult women, the range runs from 35.5% to 44.9% 3. These sex-based differences exist primarily because testosterone stimulates erythropoietin (EPO) production in the kidneys, which in turn drives red blood cell synthesis in the bone marrow.

Several physiologic variables shift the range independent of disease:

Altitude. Residents of high-altitude cities like Denver (5,280 ft) or Bogota (8,660 ft) carry hematocrit values 1 to 3 percentage points above sea-level norms. The body compensates for lower ambient oxygen partial pressure by producing more red blood cells 4.

Age. Newborns have hematocrit values near 55% to 65%, which decline over the first weeks of life. In older adults, mild decreases may reflect declining renal EPO production or chronic inflammation 5.

Pregnancy. Plasma volume expands by roughly 50% during pregnancy while red cell mass increases by only about 25%, producing a dilutional drop in hematocrit. Values around 33% to 34% in the second trimester are physiologically expected and do not indicate pathologic anemia 6.

Smoking. Carbon monoxide from cigarettes binds hemoglobin and reduces its oxygen-carrying capacity, triggering compensatory erythrocytosis. Chronic smokers frequently show hematocrit values 2 to 4 points above matched nonsmokers 7.

Your lab report will flag results outside its reference range, but a value at the very top or bottom of "normal" still deserves clinical context. A hematocrit of 48.5% in a 28-year-old woman, while technically within the male range, is worth investigating.

High Hematocrit: Causes, Risks, and Next Steps

A hematocrit above the upper reference limit is called erythrocytosis. The causes divide into three categories: relative (plasma loss), primary (bone marrow driven), and secondary (EPO driven).

Relative erythrocytosis is the most common explanation. Dehydration, diuretic use, or severe vomiting contracts plasma volume and concentrates red cells without any actual increase in red cell mass. Rehydrating and repeating the draw typically resolves the finding.

Primary erythrocytosis points to polycythemia vera (PV), a myeloproliferative neoplasm driven by the JAK2 V617F mutation in over 95% of cases. The 2016 WHO diagnostic criteria lowered the hematocrit threshold for PV suspicion to 49% in men and 48% in women 8. PV carries a significant thrombotic risk. A European collaboration of 1,638 PV patients found that maintaining hematocrit below 45% reduced the rate of cardiovascular death and major thrombosis by 3.7-fold compared to a target of 45% to 50% (CYTO-PV trial, HR 3.91; 95% CI 1.45, 10.53) 9.

Secondary erythrocytosis results from EPO overproduction. Chronic hypoxia from obstructive sleep apnea, COPD, or right-to-left cardiac shunts drives this pathway. EPO-secreting tumors (renal cell carcinoma, hepatocellular carcinoma, cerebellar hemangioblastoma) are rare but must be excluded when no hypoxic cause is found 10.

The Endocrine Society's 2018 guideline on testosterone therapy states: "Clinicians should measure hematocrit at baseline, at 3 to 6 months, and then annually for men on testosterone therapy. If hematocrit rises above 54%, stop testosterone therapy until hematocrit decreases to a safe level" 11. That 54% threshold reflects the point at which blood viscosity increases exponentially and thrombotic risk rises sharply.

Testosterone Therapy and Hematocrit: A Practical Guide

Erythrocytosis is the single most common laboratory adverse effect of testosterone replacement therapy (TRT). In the Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies enrolling 790 men aged 65 and older, testosterone gel raised mean hematocrit by approximately 3 percentage points over 12 months 12. The TRAVERSE trial (N=5,246), the largest cardiovascular safety study of TRT to date, reported polycythemia (hematocrit >54%) in 7.2% of testosterone-treated men versus 2.1% on placebo 13.

Dr. Shalender Bhasin, principal investigator of the TTrials, has noted: "The dose-dependent increase in hematocrit with testosterone is mediated by suppression of hepcidin and stimulation of erythropoietin, and it requires systematic monitoring because the rise is often asymptomatic until viscosity reaches a dangerous level" 12.

Monitoring protocol for men on TRT:

1. Baseline CBC before starting therapy.
2. 3-month recheck. If hematocrit exceeds 50%, ensure the patient is well hydrated and repeat in 2 weeks.
3. 6-month recheck. If confirmed above 54%, hold testosterone, consider therapeutic phlebotomy (removal of one unit of blood), and restart at a lower dose once hematocrit falls below 50%.
4. Annual monitoring once stable.

Switching from intramuscular injections (which produce supraphysiologic peaks) to transdermal gels or subcutaneous pellets may reduce hematocrit spikes, though head-to-head data remain limited. Nasal testosterone (Natesto) has shown lower rates of erythrocytosis in phase III data, with only 1.9% of patients exceeding 54% 14.

Low Hematocrit: Causes, Workup, and Treatment

A hematocrit below the lower reference limit defines anemia. The World Health Organization classifies anemia as hemoglobin below 13 g/dL in men and below 12 g/dL in women, which corresponds roughly to hematocrit values below 39% and 36%, respectively 15.

The differential is broad, but the mean corpuscular volume (MCV) on the same CBC narrows it quickly.

Microcytic anemia (MCV <80 fL) is most often caused by iron deficiency. Globally, iron-deficiency anemia affects an estimated 1.2 billion people 16. In premenopausal women, menstrual blood loss is the predominant driver. In men and postmenopausal women, gastrointestinal blood loss must be ruled out. A ferritin level below 30 ng/mL confirms depleted iron stores with high specificity 17.

Normocytic anemia (MCV 80, 100 fL) suggests chronic disease (renal insufficiency, chronic inflammation, malignancy), acute blood loss, or hemolysis. Checking a reticulocyte count, LDH, haptoglobin, and creatinine sorts these categories efficiently.

Macrocytic anemia (MCV >100 fL) points to vitamin B12 or folate deficiency, alcohol use, hypothyroidism, or myelodysplastic syndromes. B12 levels below 200 pg/mL combined with elevated methylmalonic acid confirm true B12 deficiency 18.

Treatment targets the underlying cause. Iron-deficiency anemia responds to oral ferrous sulfate 325 mg daily (65 mg elemental iron), though IV iron (ferric carboxymaltose, 750 mg per infusion) bypasses absorption issues and corrects stores faster in patients with GI malabsorption or intolerance 19.

How to Lower Hematocrit

The appropriate strategy depends on the cause. If dehydration produced the elevation, the fix is simple: increase daily fluid intake to at least 2.5 to 3 liters and recheck in 1 to 2 weeks. Genuine erythrocytosis requires a more targeted approach.

Therapeutic phlebotomy remains the first-line intervention for polycythemia vera and for TRT-induced erythrocytosis above 54%. Each unit removed (approximately 500 mL) typically lowers hematocrit by 3 percentage points 20. The target in PV is below 45%, based on the CYTO-PV trial data described above 9.

Dose reduction or formulation change applies to TRT patients. Lowering the testosterone dose by 25% to 50%, switching from cypionate injections to a daily transdermal gel, or shortening the injection interval (for example, from biweekly to weekly at half the per-injection dose) all blunt the erythropoietic stimulus by avoiding supraphysiologic hormone peaks.

Treat the root cause. For sleep apnea-driven erythrocytosis, initiating CPAP therapy can normalize hematocrit within 3 to 6 months as nocturnal hypoxia resolves 21. For smokers, cessation alone reduces hematocrit by an average of 1 to 3 points over several months 7.

Avoid the temptation to donate blood as a hematocrit-lowering strategy without clinical guidance. Blood banks screen for polycythemia, and frequent donations without iron supplementation can create iron deficiency even as the hematocrit normalizes.

How to Raise Hematocrit

Raising a low hematocrit means treating the anemia driving it. There is no shortcut independent of diagnosis.

Iron repletion is the most common intervention. Oral iron should be taken on an empty stomach with vitamin C (which enhances absorption) and separated from calcium, coffee, and tea by at least two hours. A reticulocyte response appears within 5 to 7 days, and hematocrit begins climbing within 2 to 4 weeks. Full correction of iron-deficiency anemia typically takes 3 to 6 months of supplementation 22.

B12 or folate supplementation corrects macrocytic anemia when deficiency is confirmed. Intramuscular cyanocobalamin 1 to 000 mcg weekly for 4 weeks, then monthly, reverses B12-deficient anemia. Oral high-dose B12 (1,000 to 2 to 000 mcg daily) is an alternative for patients without neurologic symptoms or intrinsic factor deficiency 18.

Erythropoiesis-stimulating agents (ESAs) such as epoetin alfa or darbepoetin alfa are reserved for anemia of chronic kidney disease when hemoglobin falls below 10 g/dL. The 2012 KDIGO guidelines recommend targeting hemoglobin of 10 to 11.5 g/dL, as trials like TREAT (N=4,038) showed that targeting higher levels (13 g/dL) increased stroke risk without reducing cardiovascular events 23.

Testosterone therapy itself can treat anemia of hypogonadism. The TTrials demonstrated that testosterone gel corrected unexplained anemia in 54% of hypogonadal men older than 65, compared to 15% on placebo 24.

When to Recheck and When to Worry

Not every out-of-range hematocrit requires urgent action. A single value at 49% in a well-hydrated man warrants a repeat draw in 4 to 6 weeks, not an emergency referral. A value at 57% with headaches and blurred vision warrants same-day hematology consultation.

The American Society of Hematology recommends urgent evaluation when hematocrit exceeds 52% in women or 55% in men, particularly with symptoms of hyperviscosity: headache, dizziness, visual disturbances, or erythromelalgia (burning pain in the hands and feet) 8.

For low hematocrit, symptomatic anemia (tachycardia, exertional dyspnea, chest pain, hemoglobin below 7 g/dL) requires transfusion evaluation. Asymptomatic mild anemia (hemoglobin 10 to 12 g/dL) can be worked up in the outpatient setting.

The 2018 Endocrine Society guideline co-author Dr. Bradley Anawalt, University of Washington, wrote: "Hematocrit monitoring on TRT is not optional. It is part of the standard of care, and failing to check it is the most common safety lapse we see in testosterone prescribing" 11. Whether you are on hormone therapy or simply reviewing a routine CBC, your hematocrit is a number worth understanding, and one your clinician should explain to you at every visit.